CA2789492C - Disulphide bond-stabilized functional soluble mhc class ii heterodimers - Google Patents

Disulphide bond-stabilized functional soluble mhc class ii heterodimers Download PDF

Info

Publication number
CA2789492C
CA2789492C CA2789492A CA2789492A CA2789492C CA 2789492 C CA2789492 C CA 2789492C CA 2789492 A CA2789492 A CA 2789492A CA 2789492 A CA2789492 A CA 2789492A CA 2789492 C CA2789492 C CA 2789492C
Authority
CA
Canada
Prior art keywords
mhc class
molecule
recombinant
molecules
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2789492A
Other languages
English (en)
French (fr)
Other versions
CA2789492A1 (en
Inventor
Geir Age Løset
Terje Frigstad
Inger Sandlie
Bjarne Bogen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oslo
Original Assignee
University of Oslo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oslo filed Critical University of Oslo
Publication of CA2789492A1 publication Critical patent/CA2789492A1/en
Application granted granted Critical
Publication of CA2789492C publication Critical patent/CA2789492C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2789492A 2010-02-18 2011-02-18 Disulphide bond-stabilized functional soluble mhc class ii heterodimers Active CA2789492C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US30572810P 2010-02-18 2010-02-18
GBGB1002730.8A GB201002730D0 (en) 2010-02-18 2010-02-18 Product
GB1002730.8 2010-02-18
US61/305,728 2010-02-18
US31657610P 2010-03-23 2010-03-23
US61/316,576 2010-03-23
PCT/GB2011/050325 WO2011101681A2 (en) 2010-02-18 2011-02-18 Disulphide bond-stabilized functional soluble mhc class ii heterodimers

Publications (2)

Publication Number Publication Date
CA2789492A1 CA2789492A1 (en) 2011-08-25
CA2789492C true CA2789492C (en) 2017-04-18

Family

ID=42113985

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2789492A Active CA2789492C (en) 2010-02-18 2011-02-18 Disulphide bond-stabilized functional soluble mhc class ii heterodimers

Country Status (18)

Country Link
US (2) US8828379B2 (enExample)
EP (1) EP2536746B1 (enExample)
JP (1) JP5537675B2 (enExample)
KR (1) KR101647176B1 (enExample)
CN (1) CN102947330B (enExample)
AU (1) AU2011217027B2 (enExample)
CA (1) CA2789492C (enExample)
CY (1) CY1117697T1 (enExample)
DK (1) DK2536746T3 (enExample)
ES (1) ES2572388T3 (enExample)
GB (1) GB201002730D0 (enExample)
HR (1) HRP20160475T1 (enExample)
HU (1) HUE027952T2 (enExample)
PL (1) PL2536746T3 (enExample)
RS (1) RS54744B1 (enExample)
RU (1) RU2604813C2 (enExample)
SI (1) SI2536746T1 (enExample)
WO (1) WO2011101681A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
EP3901280B1 (en) 2012-10-17 2025-03-12 10x Genomics Sweden AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
LT3167065T (lt) * 2014-07-09 2020-07-27 Lupin Limited Dviguba cistroninė bakterinė raiškos sistema
WO2017004252A1 (en) 2015-06-30 2017-01-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with mhc chimeric receptors and methods of use in immunotherapy
US12577289B2 (en) 2015-06-30 2026-03-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Surrogate co-receptors for t cells and methods of use
RU2761555C2 (ru) 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
US20180127481A1 (en) * 2016-11-09 2018-05-10 Uti Limited Partnership RECOMBINANT pMHC CLASS II MOLECULES
AU2018260380B2 (en) 2017-04-27 2025-02-13 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
DK3817757T3 (da) 2018-07-06 2026-03-09 Univ California Peptid-deficient mhc-klasse-i/chaperon-sammensætninger og fremgangsmåder
DE102018122546B3 (de) 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
WO2020064915A1 (en) * 2018-09-28 2020-04-02 Danmarks Tekniske Universitet High throughput epitope identification and t cell receptor specificity determination using loadable detection molecules
WO2020089343A1 (en) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3719033A1 (en) * 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilized mhc i
WO2021035049A1 (en) * 2019-08-21 2021-02-25 Uti Limited Partnership Improved recombinant pmhc molecules
EP4028412A2 (en) * 2019-09-13 2022-07-20 The Regents of The University of California Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications
WO2021113297A1 (en) * 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
WO2021138688A1 (en) 2020-01-03 2021-07-08 The Regents Of The University Of California Systems and methods for identification of mhc-i peptide epitopes
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
DE102020109447A1 (de) 2020-04-03 2021-10-07 Jacobs University Bremen Ggmbh Synthetisches mhc-klasse-ii-protein
US12534510B2 (en) 2020-04-16 2026-01-27 The Regents Of The University Of California Peptide-receptive MHC-I complex compositions and methods
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
TW202321312A (zh) * 2021-09-08 2023-06-01 俄羅斯聯邦商拜奧卡德聯合股份公司 包含基於ｍｈｃ或ｍｈｃ樣蛋白的異源二聚體的二價雙特異性嵌合抗體
CN118813436A (zh) * 2023-07-24 2024-10-22 佳吾益(北京)科技有限公司 展示单mhc等位基因功能蛋白的工程化细胞
CN119220425A (zh) * 2023-07-28 2024-12-31 佳吾益(北京)科技有限公司 发现mhc新抗原肽表位的工程化细胞
WO2025137580A1 (en) * 2023-12-22 2025-06-26 Antiger Therapeutics, Inc. Class ii hla with inter-chain disulfide bond

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
DK0935607T3 (da) 1996-08-16 2004-12-06 Harvard College Oplöselige monovalente og multivalente MHC klasse II-fusionsproteiner samt anvendelser deraf
AU741130B2 (en) * 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
NZ507886A (en) * 1998-05-19 2003-05-30 Avidex Ltd Multivalent T cell receptor complexes
RU2303264C2 (ru) * 2001-02-19 2007-07-20 Мерк Патент Гмбх Способ идентификации эпитопов т-клеток и его применение для получения молекул со сниженной иммуногенностью
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
WO2005044982A2 (en) * 2003-09-05 2005-05-19 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
CA2638892A1 (en) * 2005-03-18 2006-09-28 Oregon Health & Science University Recombinant mhc molecules useful for manipulation of antigen-specific t cells
WO2008017517A1 (en) * 2006-08-11 2008-02-14 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
CN101548240B (zh) * 2006-12-01 2014-09-17 卡尔蔡司Smt有限责任公司 具有用于减小像差的可替换、可操纵的校正布置的光学系统
EP2193199B1 (en) 2007-08-20 2013-11-06 Nextera AS Pvii phage display

Also Published As

Publication number Publication date
KR20130009782A (ko) 2013-01-23
US20130171668A1 (en) 2013-07-04
JP2013519721A (ja) 2013-05-30
GB201002730D0 (en) 2010-04-07
CA2789492A1 (en) 2011-08-25
AU2011217027B2 (en) 2015-02-05
KR101647176B1 (ko) 2016-08-09
HRP20160475T1 (hr) 2016-06-03
WO2011101681A3 (en) 2011-12-08
SI2536746T1 (sl) 2016-09-30
EP2536746A2 (en) 2012-12-26
US9056920B2 (en) 2015-06-16
PL2536746T3 (pl) 2016-08-31
US8828379B2 (en) 2014-09-09
JP5537675B2 (ja) 2014-07-02
RU2604813C2 (ru) 2016-12-10
RS54744B1 (sr) 2016-10-31
AU2011217027A1 (en) 2012-09-06
HUE027952T2 (en) 2016-11-28
CN102947330A (zh) 2013-02-27
EP2536746B1 (en) 2016-04-20
CY1117697T1 (el) 2017-05-17
WO2011101681A2 (en) 2011-08-25
CN102947330B (zh) 2015-09-16
ES2572388T3 (es) 2016-05-31
DK2536746T3 (en) 2016-05-30
US20140349315A1 (en) 2014-11-27
RU2012138302A (ru) 2014-03-27

Similar Documents

Publication Publication Date Title
EP2536746B1 (en) Disulphide bond-stabilized functional soluble mhc class ii heterodimers
KR102250696B1 (ko) Ｔ 세포 수용체 조작
EP1882700B1 (en) Biotinylated MHC complexes and their uses
US12630606B2 (en) Peptide deficient-MHC class I/chaperone compositions and methods
US20240262885A1 (en) Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications
Landais et al. New design of MHC class II tetramers to accommodate fundamental principles of antigen presentation
KR20160087866A (ko) 조작된 고-친화도의 인간 t 세포 수용체
US11814420B2 (en) Peptide deficient-MHC class I/chaperone compositions and methods
US20210179668A1 (en) Novel mammalian expressed human immunodeficiency virus envelope protein antigens
WO2021001414A1 (en) Peptide-mhc complexes
US20230227568A1 (en) Multimeric immunomodulator targeting 4-1bb
US20240076356A1 (en) Display of peptide-mhc (pmhc) on multimeric protein scaffolds and uses thereof
Moro et al. Generation of functional HLA-DR* 1101 tetramers receptive for loading with pathogen or tumour derived synthetic peptides
HK1177939B (en) Disulphide bond-stabilized functional soluble mhc class ii heterodimers
Fortin et al. MMTV superantigens coerce an unconventional topology between the TCR and MHC class II
TW202208396A (zh) Ｔ細胞調控性多聚體多肽和使用彼之方法
Lunde et al. Stabilizing mutations increase secretion of functional soluble TCR-Ig fusion proteins

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160217

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250211

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250211

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260209